Stay up-to-date on our latest developments
Integrin-Targeted Drug Discovery Summit - Uncover the Therapeutics Promise of Integrins
Oxurion CSO, Professor Alan Stitt, PhD. is presenting Targeting RGD-Binding Integrins as an Integrative Therapy for Diabetic Retinopathy & Neovascular Age-Related Macular Degeneration, on August 18 at 11.10 am.
Follow this link for more information and reserving your spot.